DAYBUE™ (trofinetide), the only FDA approved treatment for Rett syndrome.Click here to learn more  
Currently Neuren does not have the necessary approvals or available drug supply to enable any compassionate use or named patient programs for NNZ-2591

Improving the lives of people with
neurodevelopmental disabilities

So your online presence really delivers at each step

Learn more

Improving the lives of people with
neurodevelopmental disabilities

So your online presence really delivers at each step

Learn more

Improving the lives of people with
neurodevelopmental disabilities

So your online presence really delivers at each step

Learn more

Box Section Title

Investor Information
 
...
Latest News
 
...
Share Price
 
ASX:NEU
..
Market Cap:
20 minute delay

Neuren's Phase 2 clinical trials of NNZ-2591 are now recruiting

Post-Listing Company Specialising in great investor relations - this sample website shows how a newly listed company can look great for current and potential investors at all stages.

Product Development

Latest News

Share Price

Mkt Cap:
The Market is currently
Price Delay ~20min

Features

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Vestibulum tortor quam, feugiat vitae, ultricies eget, tempor sit amet, ante. Donec eu libero sit amet quam egestas semper. Aenean ultricies mi vitae est. Mauris placerat eleifend leo.

Twitter Feeds

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Vestibulum tortor quam, feugiat vitae, ultricies eget, tempor sit amet, ante. Donec eu libero sit amet quam egestas semper. Aenean ultricies mi vitae est. Mauris placerat eleifend leo.